Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw

Journal of Cranio-Maxillofacial Surgery

Volumn 41, Issue 1, 2013, Pages 71-75

  Stockmann, Philipp ^a   Nkenke, Emeka ^a   Englbrecht, Matthias ^b   Schlittenbauer, Tilo ^a   Wehrhan, Falk ^a   Rauh, Claudia ^b   Beckmann, Matthias W ^b   Fasching, Peter A ^b,c   Kreusch, Thomas ^d   MacKensen, Andreas ^b   Wullich, Bernd ^b   Schett, Georg ^b   Spriewald, Bernd M ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Asklepios Klinik Nord Heidberg   (Germany)

Author keywords

Anti resorptive agent induced osteonecrosis of the jaw; Bisphosphonate associated osteonecrosis; Gene variations; Genetic risk factors; Major histocompatibility complex class II

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ADVERSE OUTCOME; AGE; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; DRUG SAFETY; DRUG USE; FEMALE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROSTATE CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DRUG COMBINATIONS; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; INJECTIONS, INTRAVENOUS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS;

EID: 84872015620     PISSN: 10105182     EISSN: 18784119     Source Type: Journal    
DOI: 10.1016/j.jcms.2012.10.018     Document Type: Article

References (28)

1. AAOMS American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 65 3 2007 369 376
2. M.H. Abu-Id, Y. Acil, J. Gottschalk, and T. Kreusch Bisphosphonate- associated osteonecrosis of the jaw Mund Kiefer Gesichtschir 10 2 2006 73 81
3. M.H. Abu-Id, P.H. Warnke, J. Gottschalk, I. Springer, J. Wiltfang, and Y. Acil "Bis-phossy jaws"-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw J Craniomaxillofac Surg 36 2 2008 95 103
4. Y. Acil, B. Moller, P. Niehoff, K. Rachko, V. Gassling, and J. Wiltfang The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells J Craniomaxillofac Surg 40 8 2011 e229 e235
5. J.R. Arron, and Y. Choi Bone versus immune system Nature 408 6812 2000 535 536
6. B. Balla, J.P. Kosa, J. Kiss, J. Podani, I. Takacs, and A. Lazary Transcriptional profiling of immune system-related genes in postmenopausal osteoporotic versus non-osteoporotic human bone tissue Clin Immunol 131 2 2009 354 359
7. S. Chaudhuri, A. Cariappa, M. Tang, D. Bell, D.A. Haber, and K.J. Isselbacher Genetic susceptibility to breast cancer: HLA DQB*03032 AND HLA DRB1*11 may represent protective alleles Proc Natl Acad Sci U S A 97 21 2000 11451 11454
8. B.C. English, C.E. Baum, D.E. Adelberg, T.M. Sissung, P.G. Kluetz, and W.L. Dahut A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer Ther Clin Risk Manag 6 2010 579 583
9. A.O. Hoff, B.B. Toth, K. Altundag, M.M. Johnson, C.L. Warneke, and M. Hu Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 6 2008 826 836
10. J. Katz, Y. Gong, D. Salmasinia, W. Hou, B. Burkley, and P. Ferreira Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw Int J Oral Maxillofac Surg 40 6 2011 605 611
11. S. Khosla, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, and D. Felsenberg Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 10 2007 1479 1491
12. M. Kos, J.F. Kuebler, K. Luczak, and W. Engelke Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk J Craniomaxillofac Surg 38 4 2010 255 259
13. M. Kotb, A. Norrby-Teglund, A. McGeer, H. El-Sherbini, M.T. Dorak, and A. Khurshid An immunogenetic and molecular basis for differences in outcomes of invasive group a streptococcal infections Nat Med 8 12 2002 1398 1404
14. H. Li, S. Hong, J. Qian, Y. Zheng, J. Yang, and Q. Yi Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ t cells Blood 116 2 2010 210 217
15. K. Matsushita, A. Sugiyama, T. Uchiyama, H. Igarashi, H. Ohkuni, and S. Nagaoka Induction of lymphocytes cytotoxic to oral epithelial cells by streptococcus mitis superantigen J Dent Res 75 3 1996 927 934
16. H. Mawardi, G. Giro, M. Kajiya, K. Ohta, S. Almazrooa, and E. Alshwaimi A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw J Dent Res 90 11 2011 1339 1345
17. P. Nicoletti, V.M. Cartsos, P.K. Palaska, Y. Shen, A. Floratos, and A.I. Zavras Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of rbms3 Oncologist 17 2 2012 279 287
18. S. Otto, C. Schreyer, S. Hafner, G. Mast, M. Ehrenfeld, and S. Sturzenbaum Bisphosphonate-related osteonecrosis of the jaws-characteristics, risk factors, clinical features, localization and impact on oncological treatment J Craniomaxillofac Surg 40 4 2012 303 309
19. I.R. Reid Osteonecrosis of the jaw: who gets it, and why? Bone 44 1 2009 4 10
20. I.R. Reid, M.J. Bolland, and A.B. Grey Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 3 2007 318 320
21. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, and B. Mehrotra American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 67 5 Suppl. 2009 2 12
22. M.E. Sarasquete, R. Garcia-Sanz, L. Marin, M. Alcoceba, M.C. Chillon, and A. Balanzategui Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis Blood 112 7 2008 2709 2712
23. P.P. Sedghizadeh, S.K. Kumar, A. Gorur, C. Schaudinn, C.F. Shuler, and J.W. Costerton Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy J Oral Maxillofac Surg 66 4 2008 767 775
24. M.J. Simon, P. Niehoff, B. Kimmig, J. Wiltfang, and Y. Acil Expression profile and synthesis of different collagen types i, ii, iii, and v of human gingival fibroblasts, osteoblasts, and saos-2 cells after bisphosphonate treatment Clin Oral Investig 14 1 2010 51 58
25. P. Stockmann, F. Wehrhan, S. Schwarz-Furlan, F. Stelzle, S. Trabert, and F.W. Neukam Increased human defensive levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study J Transl Med 9135 2011
26. E. Such, J. Cervera, E. Terpos, J.V. Bagan, A. Avaria, and I. Gomez CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma Haematologica 96 10 2011 1557 1559
27. F. Wehrhan, P. Hyckel, K. Amann, J. Ries, P. Stockmann, and K. Schlegel Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment Oral Dis 17 4 2011 433 442
28. S.J. Wimalawansa Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management Expert Opin Drug Saf 7 4 2008 491 512